HR Licensing Nurses Protein 
Pfizer
JANUARY 27, 2023
Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.
Pfizer
DECEMBER 13, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., Microsomal triglyceride transfer protein inhibitor: lomitapide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer
AUGUST 15, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir.
Pfizer
DECEMBER 20, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., Microsomal triglyceride transfer protein inhibitor: lomitapide.
Pfizer
JANUARY 27, 2023
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir. Limited published data reports that ritonavir is present in human milk.
Pfizer
NOVEMBER 23, 2022
Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., Microsomal triglyceride transfer protein inhibitor: lomitapide.
The Pharma Data
DECEMBER 29, 2020
one-sided), as seronegative patients treated with the antibody cocktail had a lower risk of death or receiving mechanical ventilation (HR: 0.78; 80% CI: 0.51-1.2). Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding.
Expert insights. Personalized for you.
112 
Let's personalize your content